Materia Medica Holding has received permission from the Ministry of Health of the Russian Federation to conduct a clinical trial in order to evaluate Ergoferon for non-specific prevention of coronavirus infection in people vaccinated against COVID-19. This was reported by the company’s press service.
They stated that the production of specific protective antibodies is known to begin only at the end of the second week after the administration of component I of the vaccine and reaches an optimal level after the introduction of component II (which has a booster effect). Thus, a complete immune response is achieved only by the fifth to seventh week from the start of vaccination. Until this time, it is important not only to observe all precautions so as not to get infected with coronavirus, but also to maintain the body’s immune system.
“It is between the administration of the I and II components of the vaccine when the use of Ergoferon due to the activation of nonspecific immunity can reduce the risk of COVID-19 in vaccinated patients. The prophylactic use of Ergoferon is aimed solely at activating the immune defense and not at suppressing the production of specific antibodies. Ergoferon has a high safety profile, which has been proven in numerous clinical studies and confirmed by many years of experience in its use,” Materia Medica Holding noted.
